Ozempic and GLP-1 stomach injury lawsuits reach 3,928 in federal court
The federal GLP-1 stomach-injury case grew to 3,928 pending lawsuits as of August 3, 2026, with a key hearing on expert testimony set for September.
The federal case that combines lawsuits alleging GLP-1 medications caused stomach and bowel injuries grew to 3,928 pending suits as of August 3, 2026, an increase of 80 cases from a month earlier [1]. The cases are consolidated in MDL 3094, based in the Eastern District of Pennsylvania, where Judge Karen Spencer Marston presides [1][2].
The litigation was created on February 2, 2024, to combine claims that GLP-1 drugs caused gastroparesis (often called stomach paralysis), intestinal obstruction and ileus [2]. Complaints in the docket include allegations of gastroparesis, ileus and gallbladder injuries [1]. The suits name Novo Nordisk, which makes Ozempic, Wegovy and Rybelsus (all semaglutide), and Eli Lilly, which makes Mounjaro and Zepbound (tirzepatide) [1][2].
The docket has grown through 2026: 3,063 cases as of January 5, 3,546 as of April 1, 3,636 as of May 1, 3,763 as of June 1 and 3,848 as of July 1 [1]. By September 1, 2026, the Judicial Panel on Multidistrict Litigation reported 4,022 pending cases [1].
No case in the litigation has settled or gone to trial, and no court or jury has found that these medications caused anyone's injury [2]. In August 2025, the court excluded two of the plaintiffs' diagnostic experts and ruled that gastroparesis claims must be supported by an objective gastric emptying study, and design-defect theories were narrowed, leaving the litigation primarily a failure-to-warn case, according to a law firm that tracks it [2]. That firm states the litigation remains unresolved, with major expert-evidence rulings still ahead [2].
A second MDL, 3163, covers claims of NAION, a form of sudden vision loss. It was created on December 15, 2025, and grew from about 20 cases to roughly 200 in eight months [2]. Counts differ between reports: one firm cited about 200 cases in August 2026 [2], while the September 1, 2026 panel report listed 216 [1].
Why it matters for patients
The lawsuits do not change what any of these drugs is approved for, and the claims have not been proven; no manufacturer has been found liable [2]. People taking a GLP-1 who read about the docket are looking at a legal process, not a new safety finding about their own prescription.
The August 2025 gastric-emptying-study requirement matters if a patient is wondering whether a gastroparesis diagnosis would support a claim: one firm describes that objective test as part of its current criteria, along with an ER visit or hospital admission and a diagnosis before December 31, 2024 [2]. Criteria change, and whether any individual has a claim depends on their medical records and the law of their state [2].
Nothing in the litigation record reviewed here changes prescribing guidance. One litigation page states plainly that patients should not stop, start or change a prescribed medication because of litigation information, and that those decisions belong with a prescriber [2].
What happens next
A hearing on the admissibility of the plaintiffs' expert evidence in MDL 3094 is scheduled for September 14-18, 2026 [2]. According to the firm tracking the case, the outcome could strengthen or seriously weaken the stomach-injury track [2]. No trial date has been set, and no settlement amounts or outcomes have been reported [2]. The next monthly case count from the Judicial Panel on Multidistrict Litigation will show whether the docket keeps growing at the recent pace of roughly 80 to 85 cases a month [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.